Clinical Trial Update: Effect of BG00012 on Lymphocyte Subsets and Immunoglobulins in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS). [Phase 3]

View source ↗

Summary

Phase 3 trial update assessing BG00012 effects on lymphocyte subsets and immunoglobulins in relapsing-remitting multiple sclerosis; study completed with results…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis
• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• BG00012 (dimethyl fumarate)

Snippet

Sponsor: Biogen | Conditions: Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis | Phase 3 | Status: COMPLETED | Results posted: 2019-06-27